Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01913158Phase 2Completed

Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids

Role: lead

NCT02160678Phase 3Completed

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Role: lead

NCT02160665Phase 3Completed

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

Role: lead

NCT01447680Completed

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Role: lead

All 4 trials loaded